The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, China; Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Guangdong Higher Education Institutes, Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, China.
J Thromb Haemost. 2024 Dec;22(12):3599-3613. doi: 10.1016/j.jtha.2024.08.025. Epub 2024 Sep 20.
Platelets are critical for thrombosis and hemostasis. The THPO-MPL pathway is the primary pathway for generating thrombocytes. Dysregulation of thrombopoiesis results in platelet formation and/or function-related disorders, such as thrombocytopenia. Paclitaxel is an extensively utilized chemotherapeutic agent and its activity may be related to platelets, but the effect of paclitaxel on thrombocytopoiesis warrants comprehensive exploration.
We focused on identifying factors that regulate thrombocyte production and elucidating paclitaxel's regulatory mechanisms on thrombocytopoiesis, with a particular emphasis on discovering mechanisms that bypass THPO-MPL pathways.
We performed drug screenings using the Tg(mpl:eGFP) zebrafish model in vivo to identify Food and Drug Administration-approved compounds capable of boosting thrombocyte production. An injury experiment was used to evaluate thrombocyte function. Bromodeoxyuridine assays, terminal deoxynucleotidyl transferase dUTP nick-end labeling, and RNA sequencing analyses were performed to explore cytological and molecular mechanisms. Routine blood testing and flow cytometry were used to analyze mouse phenotypes.
We found that paclitaxel expands thrombocytes by accelerating the proliferation of thrombocytic lineage cells in zebrafish and elevates platelet levels in mice. This effect occurs by bypassing the thrombopoietin receptor (Mpl). We found that paclitaxel promotes thrombopoiesis, potentially involving the JAK2-ERK1/2 MAPK signaling cascade, a pathway integral to MPL and other regulators. Our results further demonstrate that ERK1/2 is at least partially downstream of JAK2 in paclitaxel-induced thrombopoiesis.
Paclitaxel could promote thrombopoiesis by bypassing Mpl but presumably via the JAK2-ERK1/2 MAPK pathways. It will aid in understanding the relationship between paclitaxel and platelets clinically, and paclitaxel may have potential value for safeguarding platelets and improving thrombocytosis in related diseases.
血小板对于血栓形成和止血至关重要。THPO-MPL 途径是生成血小板的主要途径。血小板生成的失调会导致血小板形成和/或功能相关的疾病,如血小板减少症。紫杉醇是一种广泛应用的化疗药物,其活性可能与血小板有关,但紫杉醇对血小板生成的影响需要全面探索。
我们专注于鉴定调节血小板生成的因素,并阐明紫杉醇对血小板生成的调控机制,特别关注发现绕过 THPO-MPL 途径的机制。
我们在体内使用 Tg(mpl:eGFP)斑马鱼模型进行药物筛选,以鉴定能够促进血小板生成的美国食品药品监督管理局批准的化合物。使用损伤实验评估血小板功能。进行溴脱氧尿苷测定、末端脱氧核苷酸转移酶 dUTP 缺口末端标记和 RNA 测序分析,以探讨细胞学和分子机制。进行常规血液检测和流式细胞术分析小鼠表型。
我们发现紫杉醇通过加速斑马鱼中血小板谱系细胞的增殖来扩张血小板,并提高小鼠的血小板水平。这种作用是通过绕过血小板生成素受体(Mpl)实现的。我们发现紫杉醇促进血小板生成,可能涉及 JAK2-ERK1/2 MAPK 信号级联,这是 MPL 和其他调节剂的重要途径。我们的结果进一步表明,ERK1/2 在紫杉醇诱导的血小板生成中至少部分位于 JAK2 的下游。
紫杉醇可能通过绕过 Mpl 但可能通过 JAK2-ERK1/2 MAPK 途径来促进血小板生成。这将有助于从临床角度理解紫杉醇与血小板之间的关系,并且紫杉醇可能在保护血小板和改善相关疾病中的血小板增多方面具有潜在价值。